Last reviewed · How we verify
Placebo for Nivolumab
Placebo for Nivolumab is a Biologic drug developed by Bristol-Myers Squibb. It is currently in Phase 3 development for Control arm in Phase 3 clinical trials of Nivolumab.
A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.
A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect. Used for Control arm in Phase 3 clinical trials of Nivolumab.
At a glance
| Generic name | Placebo for Nivolumab |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Placebo is an inert substance used as a control in clinical trials to establish the efficacy of an active drug by comparison. In this context, it serves as the control arm in Phase 3 trials of Nivolumab (a PD-1 inhibitor). Any observed effects in the placebo group are attributable to the placebo effect, natural disease progression, or other non-pharmacological factors.
Approved indications
- Control arm in Phase 3 clinical trials of Nivolumab
Common side effects
Key clinical trials
- Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery (PHASE2)
- Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) (NA)
- SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety (PHASE2)
- Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC (PHASE2)
- Phase II Randomized, Placebo- Controlled Study of Intralesional Nivolumab for High-risk Oral Premalignant Lesions (PHASE2)
- Surgical Nivolumab And Ipilimumab For Recurrent GBM (PHASE1)
- Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer (PHASE3)
- A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo for Nivolumab CI brief — competitive landscape report
- Placebo for Nivolumab updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI
Frequently asked questions about Placebo for Nivolumab
What is Placebo for Nivolumab?
How does Placebo for Nivolumab work?
What is Placebo for Nivolumab used for?
Who makes Placebo for Nivolumab?
What development phase is Placebo for Nivolumab in?
Related
- Manufacturer: Bristol-Myers Squibb — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Control arm in Phase 3 clinical trials of Nivolumab